Balancing Efficacy and Safety: Toxicity, Patient Selection, and the Future of Ivonescimab

In this episode of OncUpdates, we dive deep into the evolving landscape of lung cancer treatment, focusing on the recent advancements in immunotherapy and the implications of the HARMONi-6 trial. Join our hosts as they discuss the benefits and challenges of using novel agents like ivonescimab in squamous non-small cell lung cancer, including the critical balance of efficacy versus toxicity. Key topics include: • The historical context of lung cancer therapies, from erlotinib to the latest developments • An in-depth analysis of adverse events (AEs) associated with VEGF inhibitors and PD-1 therapies • Patient selection criteria and the importance of individualized treatment plans • Insights into the upcoming HARMONi-3 data and its potential impact on clinical practice Our expert guests, Dr. Jarushka Naidoo and Dr. Bo Wang, share their perspectives on the current state of lung cancer treatment and the future directions for research and patient care. This episode is a must-listen for healthcare professionals and anyone interested in the latest advancements in oncology. Website: https://oncupdates.com/ Mail: [email protected] X/twitter: https://x.com/OncUpdates Don't forget to like, subscribe, and hit the notification bell for more updates on cancer research and treatment! #LungCancer, #Immunotherapy, #Ivonescimab, #HARMONi6, #SquamousNSCLC